News
Latest news from CHV and our portfolio companies
Featured News
Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial BEDFORD, Mass., January 28th, 2026 – Instylla,…
Insights & Impacts: The latest from CHV
BEDFORD, Mass., – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral
Study to support U.S. FDA approval of the novel CLAASâ implant for left atrial appendage
– Patent Validates Novelty and Breadth of Proprietary Sagittari™ Treatment Platform and Expands Potential for
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health
The brain (put way too simply) is a complicated organ that remains hard to fully
Project focused on reducing maternal and neonatal mortality and morbidity by mitigating risks associated with
AtaCor Medical, Inc. (“AtaCor”) announced today that it will present initial findings from its first-in-human
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health
Deployment of a Novel 4-Minute City Program that Engages Community Members to Speed AED Response
Epitel is developing a simplified, wearable EEG system, enabling both faster diagnosis and long-term monitoring